![]()
16
| 4 | 2010
Klinisk Biokemi i Norden
18. Wiedermann FJ, Kaneider N, Egger P, Tie-
fenthaler W, Wiedermann CJ, Lindner KH,
et al. Migration of human monocytes in
response to procalcitonin. Crit Care Med
2002;30:1112-7.
19. Meisner M, Lohs T, Huettemann E, Sch-
midt J, Hueller M, Reinhart K. The plasma
elimination rate and urinary secretion of
procalcitonin in patients with normal and
impaired renal function. Eur J Anaesthesiol
2001;18:79-87.
20. Level C, Chauveau P, Delmas Y, Lasseur C,
Pelle G, Peuchant E, et al. Procalcitonin:
a new marker of inflammation in haemo-
dialysis patients? Nephrol Dial Transplant
2001;16:980-6.
21. Level C, Chauveau P, Guisset O, Cazin MC,
Lasseur C, Gabinsky C, et al. Mass transfer,
clearance and plasma concentration of pro-
calcitonin during continuous venovenous
hemofiltration in patients with septic shock
and acute oliguric renal failure. Crit Care
2003;7:R160-R166.
22. Sitter T, Schmidt M, Schneider S, Schiffl
H. Differential diagnosis of bacterial infec-
tion and inflammatory response in kid-
ney diseases using procalcitonin. J Nephrol
2002;15:297-301.
23. Christ-Crain M, Opal SM. Clinical review:
the role of biomarkers in the diagnosis and
management of community-acquired pneu-
monia. Crit Care;14:203.
24. Gurgoze MK, Akarsu S, Yilmaz E, Godek-
merdan A, Akca Z, Ciftci I, et al. Proin-
flammatory cytokines and procalcitonin in
children with acute pyelonephritis. Pediatr
Nephrol 2005;20:1445-8.
25. Steinbach G, Rau B, Debard AL, Javourez
JF, Bienvenu J, Ponzio A, et al. Multicenter
evaluation of a new immunoassay for procal-
citonin measurement on the Kryptor System.
Clin Chem Lab Med 2004;42:440-9.
26. Meisner M, Tschaikowsky K, Hutzler A,
Schick C, Schuttler J. Postoperative plasma
concentrations of procalcitonin after dif-
ferent types of surgery. Intensive Care Med
1998;24:680-4.
27. Lindberg M, Hole A, Johnsen H, Asberg A,
Rydning A, Myrvold HE, et al. Reference
intervals for procalcitonin and C-reactive
protein after major abdominal surgery.
Scand J Clin Lab Invest2002;62:189-94.
28. Reith HB, Mittelkotter U, Debus ES, Kus-
sner C, Thiede A. Procalcitonin in early
detection of postoperative complications.
Dig Surg 1998;15:260-5.
29. Novotny AR, Emmanuel K, Hueser N, Kne-
bel C, Kriner M, Ulm K, et al. Procalcitonin
ratio indicates successful surgical treatment
of abdominal sepsis. Surgery 2009;145:20-6.
30. Meisner M, Tschaikowsky K, Schnabel S,
Schmidt J, Katalinic A, Schuttler J. Pro-
calcitonin--influence of temperature, sto-
rage, anticoagulation and arterial or venous
asservation of blood samples on procalcito-
nin concentrations. Eur J Clin Chem Clin
Biochem 1997;35:597-601.
31. de Kruif MD, Lemaire LC, Giebelen IA,
Struck J, Morgenthaler NG, Papassotiriou J,
et al. The influence of corticosteroids on the
release of novel biomarkers in human endo-
toxemia. Intensive Care Med 2008;34:518-
22.
32. Bone RC, Balk RA, Cerra FB, Dellinger RP,
Fein AM, Knaus WA, et al. Definitions for
sepsis and organ failure and guidelines for
the use of innovative therapies in sepsis.
The ACCP/SCCM Consensus Conference
Committee. American College of Chest
Physicians/Society of Critical Care Medi-
cine. 1992. Chest 2009;136(5 Suppl):e28.
33. Jensen JU, Lundgren B, Hein L, Mohr
T, Petersen PL, Andersen LH, et al. The
Procalcitonin And Survival Study (PASS)
- a randomised multi-center investigator-
initiated trial to investigate whether daily
measurements biomarker Procalcitonin
and pro-active diagnostic and therapeutic
responses to abnormal Procalcitonin levels,
can improve survival in intensive care unit
patients. Calculated sample size (target
population): 1000 patients. BMC Infect Dis
2008,8:91.
(Fortsat fra side 16)
